Antiproliferative activity of a series of 5‑(1H‑1,2,3‑triazolyl) methyl‑ and 5‑acetamidomethyl‑oxazolidinone derivatives

Hedaya,Omar M.; Mathew,Princy M.; Mohamed,Fatima H.; Phillips,Oludotun A.; Luqmani,Yunus A.

doi:10.3892/mmr.2016.4938

Antiproliferative activity of a series of 5‑(1H‑1,2,3‑triazolyl) methyl‑ and 5‑acetamidomethyl‑oxazolidinone derivatives

Authors:
- Omar M. Hedaya
- Princy M. Mathew
- Fatima H. Mohamed
- Oludotun A. Phillips
- Yunus A. Luqmani
View Affiliations

Affiliations: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, Safat 13110, Kuwait
Published online on: February 23, 2016 https://doi.org/10.3892/mmr.2016.4938
Pages: 3311-3318

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the face of increasing resistance to the existing antibiotics, oxazolidinones (exemplified by linezolid) have been developed as promising antibacterial agents, but may have other useful actions. In the present study, a series of 5‑(1H‑1,2,3‑triazoly) l‑methyl‑, 5‑acetamidomethyl‑morpholino and N‑substituted‑piperazino oxazolidinone derivatives were investigated to determine whether they are active against eukaryotic cells. An MTT assay, validated by cell counting, was used to assess the effect of nine oxazolidinone derivatives (concentrations 100 nM‑10 µM) on the proliferation of MCF7 human breast cancer cells. The three most active compounds were then tested on MDA231 breast cancer cells. Cytotoxicity of the selected derivatives was determined by assessing the extent of apoptosis by flow cytometry. The antimetastatic potential of these compounds was assessed on MDA231 cells using wound healing and agarose invasion assays. The 5‑triazolylmethyl piperazino‑oxazolidinone derivatives containing 4‑N‑(2‑chlorocinnamoyl), 4‑N‑(4‑nitrobenzoyl) and 4‑N‑methylsulfonyl moieties exhibited the most potent cytostatic activity against cancer, inhibiting proliferation by up to 70%, in the same order as their reported antibacterial activity against Staphylococcus aureus, but at higher concentrations. Unexpectedly, several derivatives stimulated proliferation at 100 nM, well below their antibacterial minimum inhibitory concentrations. Certain compounds also retarded the motility and invasion of MDA231 cells. Three of the tested derivatives had no effect on the eukaryotic cell lines, demonstrating their preferential activity against bacteria. Two compounds actually stimulated eukaryotic cell proliferation. The remaining three exhibited potent cytostatic activity against and cancer cells, displaying differences in response at low and high concentrations, which may suggest multiple targets on eukaryotic cells. These latter compounds may be useful as anticancer agents.

View Figures

View References

1	Pandit N, Singla RK and Shrivastava B: Current updates on oxazolidinone and its significance. Int J Med Chem. 2012:1592852012.PubMed/NCBI
2	Jiang X, Sun L, Qui JJ, Sun X, Li S, Wang X, So CW and Dong S: A novel application of furazolidone: Anti-luekemic activity in acute myeloid leukemia. PLOS ONE. 8:e723352013. View Article : Google Scholar
3	Reck F, Zhou F, Girardot M, Kern G, Eyermann CJ, Hales NJ, Ramsay RR and Gravestock MB: Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J Med Chem. 48:499–506. 2005. View Article : Google Scholar : PubMed/NCBI
4	Kombian SB and Phillips OA: In vitro electrophysiological investigations of the acute effects of linezolid and novel oxazolidinones on central nervous system neurons. Neurosci. 180:53–63. 2011. View Article : Google Scholar
5	Sun Y, Tang S, Jin X, Zhang C, Zhao W and Xiao X: Opposite effects of JNK and p38 MAPK signaling pathways on furazolidinone-stimulated S phase cell cycle arrest of human hepatoblastoma cell line. Mutat Res. 775:24–29. 2013. View Article : Google Scholar
6	Auro A, Sumano H, Ocampo L and Barragán A: Evaluation of the carcinogenic effects of furazolidone and its metabolites in two fish species. The Pharmacogenomics J. 4:24–28. 2004. View Article : Google Scholar
7	Artico M, De Martino G and Giuliano R: Research on compounds with antiblastic activity. XL Synthesis of 3-p-(2′, 5′-dimethoxy-4′-(N, N-bis-(-chloroethyl)-amino)benzylideneamino) phenyl-2-oxazolidinone (GEA 29; BAY a 5850) and its analogues. Farmaco Sci. 26:771–783. 1971.PubMed/NCBI
8	Devi K, Asmat Y, Agrawal M, Sharma S and Dwived J: Synthesis and evaluation of some novel precursors of oxazolidinone analogues of chloroquinoline for their antimicrobial and cytotoxic potential. J Chem Sci. 125:1093–1101. 2013. View Article : Google Scholar
9	Naresh A, Venkateswara Rao MV, Kotapalli SS, Ummanni R and Venkateswara Rao B: Oxazolidinone derivatives: Cytoxazone-linezolid hybrids induces apoptosis and senescence in DU145 prostate cancer cell. Eur J Med Chem. 80:295–307. 2014. View Article : Google Scholar : PubMed/NCBI
10	Brickner SJ, Hutchinson DK, Barbachyn MR, Manninen PR, Ulanowicz DA, Garmon SA, Grega KC, Hendges SK, Toops DS, Ford CW and Zurenko GE: Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem. 39:673–679. 1996. View Article : Google Scholar : PubMed/NCBI
11	Wilcox MH: Update on linezolid: The first oxazolidinone antibiotic. Expert Opin Pharmacother. 6:2315–2326. 2005. View Article : Google Scholar : PubMed/NCBI
12	Eustice DC, Feldman PA, Zajac I and Slee AM: Mechanism of action of DuP 721: Inhibition of an early event during initiation of protein synthesis. Antimicrob Agents Chemother. 32:1218–1222. 1988. View Article : Google Scholar : PubMed/NCBI
13	Kalia V, Miglani R, Purnapatre KP, Mathur T, Singhal S, Khan S, Voleti SR, Upadhyay DJ, Saini KS, Rattan A and Raj VS: Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes. Antimicrob Agents Chemother. 53:1427–1433. 2009. View Article : Google Scholar :
14	Zhou CC, Swaney SM, Shinabarger DL and Stockman BJ: 1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes. Antimicrob Agents Chemother. 46:625–629. 2002. View Article : Google Scholar : PubMed/NCBI
15	Ippolito JA, Kanyo ZF, Wang D, Franceschi FJ, Moore PB, Steitz TA and Duffy EM: Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J Med Chem. 51:3353–3356. 2008. View Article : Google Scholar : PubMed/NCBI
16	McKee EE, Ferguson M, Bentley AT and Marks TA: Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother. 50:2042–2049. 2006. View Article : Google Scholar : PubMed/NCBI
17	De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL, Vanopdenbosch LJ, Martin JJ, Groote CC, Vandecasteele S and Boelaert JR: Linezolid-Induced Inhibition of Mitochondrial Protein Synthesis. Clin Infect Dis. 42:1111–1117. 2006. View Article : Google Scholar : PubMed/NCBI
18	Kuter DJ and Tillotson GS: Hematologic effects of antimicrobials: Focus on the oxazolidinone linezolid. Pharmacotherapy. 21:1010–1013. 2001. View Article : Google Scholar : PubMed/NCBI
19	Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B and Kuter DJ: Hematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother. 46:2723–2726. 2002. View Article : Google Scholar : PubMed/NCBI
20	Leach KL, Brickner SJ, Noe MC and Miller PF: Linezolid, the first oxazolidinone antibacterial agent. Ann N Y Acad Sci. 1222:49–54. 2011. View Article : Google Scholar : PubMed/NCBI
21	Corallo CE and Paull AE: Linezolid-induced neuropathy. Med J Aust. 177:3322002.PubMed/NCBI
22	Rucker JC, Hamilton SR, Bardenstein D, Isada CM and Lee MS: Linezolid-associated toxic optic neuropathy. Neurology. 66:595–598. 2006. View Article : Google Scholar : PubMed/NCBI
23	Kraleti S and Soultanova I: Pancytopenia and lactic acidosis associated with linezolid use in a patient with empyema. J Ark Med Soc. 110:62–63. 2013.PubMed/NCBI
24	Narita M, Tsuji BT and Yu VL: Linezolid-associated peripheral and optic neuropathy, lactic acidosis and serotonin syndrome. Pharmacotherapy. 27:1189–1197. 2007. View Article : Google Scholar : PubMed/NCBI
25	Su E, Crowley K, Carcillo JA and Michaels MG: Linezolid and lactic acidosis: A role for lactate monitoring with long-term linezolid use in children. Pediatr Infect Dis J. 30:804–806. 2011. View Article : Google Scholar : PubMed/NCBI
26	Phillips OA, Udo EE, Ali AA and Al-Hassawi N: Synthesis and antibacterial activity of 5-substituted oxazolidinones. Bioorg Med Chem. 11:35–41. 2003. View Article : Google Scholar
27	Phillips OA, Udo EE, Ali AAM and Samuel SM: Structure-antibacterial activity of arylcarbonyl- and arylsulfonyl-piperazine 5-triazolylmethyl oxazolidinones. Eur J Med Chem. 42:214–225. 2007. View Article : Google Scholar
28	Phillips OA, Udo EE, Abdel-Hamid ME and Varghese R: Synthesis and antibacterial activities of N-substituted-gylcinyl 1H-1,2,3-triazolyl oxazolidinones. Eur J Med Chem. 66:246–257. 2013. View Article : Google Scholar : PubMed/NCBI
29	Khajah MA, Al Saleh S, Mathew PM and Luqmani YA: Differential Effect of Growth Factors on Invasion and Proliferation of endocrine resistant breast cancer cells. PLoS One. 7:e418472012. View Article : Google Scholar : PubMed/NCBI
30	Liang C, Park A and Guan J: In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoco. 2:329–333. 2007. View Article : Google Scholar
31	Calabrese EJ and Blain R: The occurrence of hormetic dose responses in the toxicological literature, the hormesis database: An overview. Toxicol Appl Pharmacol. 202:289–301. 2005. View Article : Google Scholar : PubMed/NCBI
32	Nascarella M, Stanek E, Hoffmann GR and Calabrese EJ: Quantification of hormesis in anticancer-agent dose-responses. Dose-Response. 72:160–171. 2009.
33	Wang Y, Gray JP, Mishin V, Heck DE, Laskin DL and Laskin JD: Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radical Bio Med. 44:1169–1179. 2008. View Article : Google Scholar